Prognostic value of COX-2 immunohistochemical expression evaluated by quantitative image analysis in colorectal cancer
KYRIAKOS ZAFIRELLIS,
GEORGE AGROGIANNIS,
AGLAIA ZACHAKI,
Corresponding Author
KYRIAKOS ZAFIRELLIS
Department of Surgery, Karditsa General Hospital, Karditsa
Kyriakos Zafirellis, Department of Surgery, Karditsa General Hospital, Tavropos Str., 43100 Karditsa, Greece. e-mail: [email protected]Search for more papers by this authorGEORGE AGROGIANNIS
First Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Greece
Search for more papers by this authorAGLAIA ZACHAKI
Department of Surgery, Karditsa General Hospital, Karditsa
Search for more papers by this authorKYRIAKOS ZAFIRELLIS,
GEORGE AGROGIANNIS,
AGLAIA ZACHAKI,
Corresponding Author
KYRIAKOS ZAFIRELLIS
Department of Surgery, Karditsa General Hospital, Karditsa
Kyriakos Zafirellis, Department of Surgery, Karditsa General Hospital, Tavropos Str., 43100 Karditsa, Greece. e-mail: [email protected]Search for more papers by this authorGEORGE AGROGIANNIS
First Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Greece
Search for more papers by this authorAGLAIA ZACHAKI
Department of Surgery, Karditsa General Hospital, Karditsa
Search for more papers by this author†
Received 4 March 2008.
Accepted 23 April 2008.
Abstract
Epidemiological studies have shown that the inducible form of cyclooxygenase (COX-2) may be involved in colorectal carcinogenesis, but it is controversial whether its expression is a prognostic factor for colorectal cancer. The aim of the study was to examine the expression of COX-2 in colorectal cancer and investigate its prognostic relevance. Tissue sections of primary tumors from 132 patients undergoing curative resection for colorectal cancer were immunohistochemically examined for COX-2 expression. The levels of intensity and extent of COX-2 staining were quantified by use of a computerized image analysis system and correlated with various clinicopathological characteristics and survival. COX-2 immunoreactivity was observed in the cytoplasm of tumour epithelial cells of all colorectal cancer tissues examined. No significant correlation was found between levels of intensity and extent of COX-2 staining and various clinicopathological characteristics, including age, gender, tumor location, tumor size, tumor grade, depth of invasion, lymph node status and TNM stage. There was an inverse correlation between intensity and extent of COX-2 staining scores (Spearman's rho=−0.414; p<0.001). To analyze the prognostic value of intensity and extent of COX-2 staining, the patients were divided into four groups with respect to quartiles (≤25; >25 to ≤50; >50 to ≤75; and >75). No significant disease-specific survival difference among the quartiles was found based on analysis of intensity (p=0.689) and extent (p=0.975) of COX-2 staining. These results suggest that the expression of COX-2 protein has no significant impact on the outcome of patients with colorectal cancer.
REFERENCES
- 1 Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481–8.
- 2 Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997; 40: 15–24.
- 3 Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609–14.
- 4 Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593–6.
- 5 Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322–7.
- 6 Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 1996; 270: G393–G400.
- 7 DuBois RN, Awad J, Morrow J, Roberts LJ, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J Clin Invest 1994; 93: 493–8.
- 8 Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 9049–54.
- 9 Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183–8.
- 10 Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 55: 2556–9.
- 11 Maekawa M, Sugano K, Sano H, Miyazaki S, Ushiama M, Fujita S, et al. Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. Jpn J Clin Oncol 1998; 28: 421–6.
- 12 Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 3785–9.
- 13 Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999; 282: 1254–7.
- 14 Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409–12.
- 15 Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803–9.
- 16 Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56: 4566–9.
- 17 Buecher B, Heymann MF, Lievre A, Nguyen JM, Wilson K, Bezieau S, et al. Cyclo-oxygenase-2 over-expression in sporadic colorectal carcinoma without lymph node involvement. Aliment Pharmacol Ther 2003; 18: 731–40.
- 18 Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004; 10: 8465–71.
- 19 Fux R, Schwab M, Thon KP, Gleiter CH, Fritz P. Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res 2005; 11: 4754–60.
- 20 Joo YE, Kim HS, Min SW, Lee WS, Park CH, Park CS, et al. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int J Gastrointest Cancer 2002; 31: 147–54.
- 21 Petersen S, Haroske G, Hellmich G, Ludwig K, Petersen C, Eicheler W. COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome. Anticancer Res 2002; 22: 1225–30.
- 22 Zafirellis K, Agrogiannis G, Zachaki A, Gravani K, Karameris A, Kombouras C. Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. J Surg Res 2008; 147: 99–107.
- 23 Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 69–77.
- 24 Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson BJ, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999; 91: 1295–303.
- 25 Samowitz WS, Curtin K, Ma KN, Schaffer D, Coleman LW, Leppert M, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001; 10: 917–23.
- 26 Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247–57.
- 27 Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000; 6: 4064–8.
- 28 Yamauchi T, Watanabe M, Kubota T, Hasegawa H, Ishii Y, Endo T, et al. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 2002; 45: 98–103.
- 29 Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002; 97: 1037–41.
- 30 Dimberg J, Samuelsson A, Hugander A, Soderkvist P. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 1999; 45: 730–2.
- 31 Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998; 58: 4823–6.
- 32 Konno H, Baba M, Shoji T, Ohta M, Suzuki S, Nakamura S. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis 2002; 19: 527–34.
- 33 Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama J, Osada T, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000; 83: 324–8.
- 34 Wu AW, Gu J, Ji JF, Li ZF, Xu GW. Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis. World J Gastroenterol 2003; 9: 1990–4.
- 35 Yamac D, Celenkoglu G, Coskun U, Akyurek N, Akcali Z, Dursun A, et al. Prognostic importance of COX-2 expression in patients with colorectal cancer. Pathol Res Pract 2005; 201: 497–502.
- 36 Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002; 8: 1323–7.
- 37 Hall TL, Fu YS. Applications of quantitative microscopy in tumor pathology. Lab Invest 1985; 53: 5–21.
- 38 Rubin MA, Zerkowski MP, Camp RL, Kuefer R, Hofer MD, Chinnaiyan AM, et al. Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol 2004; 164: 831–40.
- 39 Bauer KD, Torre-Bueno J, Diel IJ, Hawes D, Decker WJ, Priddy C, et al. Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res 2000; 6: 3552–9.
- 40 Cross SS. Observer accuracy in estimating proportions in images: implications for the semiquantitative assessment of staining reactions and a proposal for a new system. J Clin Pathol 2001; 54: 385–90.
- 41 Diaz LK, Sneige N. Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 2005; 12: 10–9.
- 42 Lehr HA, Jacobs TW, Yaziji H, Schnitt SJ, Gown AM. Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. Am J Clin Pathol 2001; 115: 814–22.
- 43 Umemura S, Itoh J, Itoh H, Serizawa A, Saito Y, Suzuki Y, et al. Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures? Appl Immunohistochem Mol Morphol 2004; 12: 8–13.
- 44 Esteban JM, Battifora H, Warsi Z, Bailey A, Bacus S. Quantification of estrogen receptors on paraffin-embedded tumors by image analysis. Mod Pathol 1991; 4: 53–7.
- 45 Esteban JM, Ahn C, Mehta P, Battifora H. Biologic significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer. Am J Clin Pathol 1994; 102: 158–62.
- 46 King TW, Brey EM, Youssef AA, Johnston C, Patrick CW Jr. Quantification of vascular density using a semiautomated technique for immunostained specimens. Anal Quant Cytol Histol 2002; 24: 39–48.
- 47 Ruifrok AC. Quantification of immunohistochemical staining by color translation and automated thresholding. Anal Quant Cytol Histol 1997; 19: 107–13.
- 48 Ma W, Lozanoff S. A full color system for quantitative assessment of histochemical and immunohistochemical staining patterns. Biotech Histochem 1999; 74: 1–9.
- 49 Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58: 362–6.
- 50 Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493–501.
- 51 Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336–40.
- 52 Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A, et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001; 121: 1339–47.
- 53 Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705–16.
